论文部分内容阅读
格林一巴利综合征(GBS)约5％病死,10～23％需要人工呼吸,10～15％的患者常遗存残疾。几种临床治疗表明,血浆除去法对GBS有效,比不用此法治疗的患者提早行走一个月,且可减少使用呼吸器的时间。因此血浆除去疗法适用于严重GBS患者,已被普遍接受。然而血浆除去疗法有其并发症和禁忌症,且仅能在有条件的医院进行,因而受到一定限制,妨碍了许多患者的治疗。大剂量静点丙种球蛋白(IVGG)可代替血浆除去疗法,它几乎没有禁忌症,可在任何医院应用,并已证明是安全的。
About 5% of GBS are dead, 10 to 23% need artificial resuscitation, and 10 to 15% often have residual disability. Several clinical treatments have shown that plasma removal is effective for GBS and one month earlier than patients not treated with this method, and can reduce the time to use respirators. Therefore, plasma therapy for patients with severe GBS has been generally accepted. However, plasma-depleted therapies have complications and contraindications and can only be performed in hospitals that are eligible, subject to certain restrictions that prevent the treatment of many patients. High-dose intravenous immunoglobulin (IVGG), an alternative to plasma therapy, has almost no contraindications and can be used in any hospital and has proven to be safe.